Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07204574) titled 'The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer' on Sept. 24.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Chang Gung Memorial Hospital
Condition:
CRC
Intervention:
Drug: HCB101
Drug: Bevacizumab
Drug: Cetuximab (Erbitux)
Drug: FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)
Recruitment ...